Population
Single isolated alpha-toxin-permeabilized vascular smooth muscle cells
Comparison
Pseudosubstrate inhibitor of PKC vs Ca2+ activation or agonist activation without PKI
Design
Preclinical
Authors
Loading...
PKC mediates agonist force enhancement in vascular smooth muscle; leaves open therapeutic targeting in vivo.
Inhibition of PKC with PKI depresses force and stiffness in agonist-stimulated vascular smooth muscle cells, suggesting PKC activation mediates agonist-induced force enhancement.
Frank V. Brozovich (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: